Previous 10 | Next 10 |
home / stock / bct:cc / bct:cc news
AUSTIN, Texas, Nov. 15, 2022 (GLOBE NEWSWIRE) -- SmallCapVoice.com Inc. (“SCV”) announces the availability of a new audio interview with Dr. Bill Williams, CEO of BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V: BCT), to discuss the positive initial efficacy data of t...
Overview BriaCell Therapeutics ( NASDAQ:BCTX, BCTXW;TSX:BCT ) is a clinical phase biotechnology company developing innovative immunotherapies for treating cancer. At the forefront of cancer treatments, immunotherapies boost the ability of the body's own cancer-...
Bria-IMT™ regimen in combination with Incyte’s retifanlimab produced evidence of disease control, tumor shrinkage, and potential survival benefit amongst BriaCell’s recent 12 patient cohort in advanced breast cancer. The regimen remains well tolerated ...
BriaCell has successfully completed its Phase I safety and tolerability evaluation of Bria-IMT™ in combination with Incyte’s retifanlimab in advanced breast cancer. The combination treatment showed a favorable safety profile in 12 patients. Phase ...
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 12, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ca...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 14, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 07, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for c...
PHILADELPHIA and VANCOUVER, British Columbia, Aug. 04, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”) , a clinical-stage biotechnology company specializing in targeted immunotherapies for ca...
Extended survival and tumor shrinkage in advanced breast cancer patients who matched the immunotherapy HLA types, lead to the development of BriaCell’s prostate cancer program based on the patient’s HLA type. Bria-Pros™ is a novel off-the-shelf persona...
News, Short Squeeze, Breakout and More Instantly...
Briacell Therapeutics Corp. Company Name:
BCT:CC Stock Symbol:
TSXC Market:
Briacell Therapeutics Corp. Website:
A look at the top 10 most actives in Canada Canadian Natural Resources Limited (CNQ) rose 0.2% to $48.92 on volume of 19,781,731 shares iShares S&P/TSX 60 Index ETF (XIU) fell 0.5% to $34.3919 on volume of 13,629,336 shares Constellation Software Inc. Unsecured Subordinated Floating R...
A look at the top 10 most actives in Canada Constellation Software Inc. Unsecured Subordinated Floating Rate Debentures Series 1 (CSU.DB) rose 0.4% to $123 on volume of 12,106,000 shares Royal Bank of Canada (RY) rose 0.4% to $154 on volume of 4,630,267 shares iShares S&P/TSX 60 Index...
Progression free survival (PFS) extended to 9.1 months in ADC resistant patient - quadruple the PFS of patients in similar studies 1, 2, 3 Significant reduction of “Eye-Bulging” metastatic breast cancer tumor was previously rep...